Aulos Bioscience Appoints Leo Redmond as Chief Financial Officer

Aulos Bioscience Appoints Leo Redmond as Chief Financial Officer
News provided by
Share this article
Share this article
LARKSPUR, Calif., May 17, 2021 /PRNewswire/ -- Aulos Bioscience, a biotechnology company developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, announced today that Leo Redmond will join the company as chief financial officer. Redmond brings to Aulos nearly three decades of financial experience in the biopharmaceutical industry. He will be based in the company's new headquarters in Larkspur, California.
"We are pleased to welcome Leo to Aulos at a time when we are rapidly building out our operations in California, preparing to start our first human trial of AU-007, planning our next fundraising scenarios, and defining the corporate strategy. Leo is a wonderful addition to our leadership team. His knowledge and expertise in leading all aspects of financial management for both private and public biopharma companies is a great fit for us as we navigate through our next phases of growth," said Aron Knickerbocker, chief executive officer of Aulos.

Related Keywords

California ,United States ,Anderson School ,Cleo Redmond ,Aron Knickerbocker ,University Of Kansas ,Genentech ,Presidio Pharmaceuticals ,Aulos Bioscience Inc ,Genentech Foundation For Biomedical Sciences ,Anderson School Of Management ,Genentech Foundation ,Biomedical Sciences ,Biolojic Design ,Tel Aviv Based ,Aulos Bioscience ,Nc ,கலிஃபோர்னியா ,ஒன்றுபட்டது மாநிலங்களில் ,ஆண்டர்சன் பள்ளி ,ஆரோன் நிகர்‌பாகர் ,பல்கலைக்கழகம் ஆஃப் கன்சாஸ் ,ஜெநிஂடெக் ,பிரெசிதிிஓ மருந்துகள் ,ஆண்டர்சன் பள்ளி ஆஃப் மேலாண்மை ,ஜெநிஂடெக் அடித்தளம் ,உயிர் மருத்துவ அறிவியல் ,தொலைபேசி அவிவ் அடிப்படையிலானது ,ந்ஸீ ,